REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals is a biopharmaceutical company focused on developing therapeutics for central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's primary asset is brilaroxazine (RP5063), a lead product candidate in clinical development across multiple neuropsychiatric indications including schizophrenia, bipolar disorder, major depressive disorder, and attention-deficit/hyperactivity disorder. Brilaroxazine is also being evaluated for behavioral and psychotic symptoms of dementia, Alzheimer's disease psychosis, and Parkinson's disease psychosis. The compound is additionally in clinical development for respiratory conditions such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis, and in preclinical development for psoriasis treatment.

The company is developing a secondary product candidate, RP1208, targeting depression and obesity indications. As a clinical-stage biopharmaceutical company, Reviva has not yet generated product revenues.

Founded in 2018 and headquartered in Cupertino, California, Reviva operates with a minimal workforce of 14 full-time employees. The company is incorporated in Delaware and publicly listed on Nasdaq, reflecting its status as an early-stage drug developer dependent on capital markets funding to advance its clinical pipeline.